🔎 Trials Near Me

Home › Mieloma multiplo › Texas

Studi clinici su Mieloma multiplo nello stato di Texas

53 studi su Mieloma multiplo cercano partecipanti presso sedi nello stato di Texas.

Città nello stato di Texas

Testo ufficiale dello studio (inglese)

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  • Research Site, Austin
  • Research Site, Dallas
  • Research Site, Houston
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT07391657

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

  • MD Anderson Cancer Center, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT05652335

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  • Baylor University Medical Center, Dallas
  • Joe Arrington Cancer Research Treatment Center, Lubbock
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07518186

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

  • Research Site, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07073547

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  • St. David's South Austin Medical Center, Austin
  • Baylor University Medical Center, Dallas
  • UT Southwestern Medical Center, Dallas
  • e altri 2
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07258511

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

  • MD Anderson, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07336472

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

  • University of Texas Southwestern Medical Center, Dallas
  • Houston Methodist Hospital, Houston
  • Joe Arrington Cancer Research Treatment Center, Lubbock
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05552222

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

  • The University of Texas MD Anderson Cancer Center, Houston
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05623020

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

  • MD Anderson Cancer Center, Houston
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05201781

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

  • Oncology Consultants (P1 Trials -Exigent Network), Houston
  • Lumi Research, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 set 2026 · NCT07477587

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

  • Texas Oncology - The Woodlands /ID# 278726, The Woodlands
  • Texas Oncology - Northeast Texas /ID# 278725, Tyler
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07095452

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  • The University of Texas MD Anderson Cancer Center, Houston
In reclutamentoFase 2
Età 12 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT02693535

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  • The University of Texas MD Anderson Cancer Center, Houston
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT07648264

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

  • MD Anderson Cancer Center, Houston
In reclutamentoFase 2
Tutte le età · Tutti i sessi · Aggiornato il 18 set 2026 · NCT07382739

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

  • MD Anderson Cancer Center, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT04879043

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  • University of Texas MD Anderson Cancer Center, Houston
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 set 2026 · NCT06615479

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • UT Southwestern Medical Center, Dallas
  • University of Texas MD Anderson Cancer Center, Houston
  • Methodist HealthCare System of San Antonio Clinical Trials Office, Texas Transplant Institute, San Antonio
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT06297226

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

  • University of Texas - Southwestern Medical Center /ID# 271914, Dallas
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT06953960

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

  • University of Texas MD Anderson Cancer Center, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 set 2026 · NCT06988488

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

  • Research Site, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 27 ago 2026 · NCT07681596

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  • Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy, Dallas
  • Baylor University Medical Center, Dallas
  • Houston Methodist Cancer Center Infusion, Houston
  • e altri 9
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 ago 2026 · NCT06152575

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

  • GSK Investigational Site, Fort Worth
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT05714839

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

  • MD Anderson Cancer Center, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT06292780

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

  • University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT05651932

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

  • Research Site, Austin
  • Research Site, Dallas
  • Research Site, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT05850234

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

  • MD Anderson Cancer Center, Houston
In reclutamentoFase 2Volontari sani benvenuti
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 ago 2026 · NCT05091372

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  • Research Site, Dallas
  • Research Site, Houston
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 ago 2026 · NCT07764978

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

  • Baylor University Medical Center, Dallas
  • Houston Methodist Hospital, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 12 ago 2026 · NCT07280013

Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma

  • M D Anderson Cancer Center, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 ago 2026 · NCT06105554

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

  • MD Anderson Cancer Center, Houston
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 10 ago 2026 · NCT06207799

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

  • M D Anderson Cancer Center, Houston
In reclutamentoFase 1/2
Età da 12 a 80 · Tutti i sessi · Aggiornato il 7 ago 2026 · NCT05092451

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  • START San Antonio, San Antonio
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT07284758

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

  • University of Texas - Southwestern Medical Center /ID# 274360, Dallas
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 lug 2026 · NCT06892522

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

  • University of Texas MD Anderson Cancer Center, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 lug 2026 · NCT06121843

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • Texas Oncology - Central/South Texas /ID# 268563, Austin
  • Texas Oncology - Dallas - Worth Street /ID# 280064, Dallas
  • Oncology Consultants /ID# 268323, Houston
  • e altri 1
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 lug 2026 · NCT05650632

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

  • University of Texas Southwestern, Dallas
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 lug 2026 · NCT05137054

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

  • St. David's South Austin Medical Center, Austin
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 lug 2026 · NCT06057402

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

  • MD Anderson in The Woodlands, Conroe
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
  • e altri 6
In reclutamentoFase 3
Tutte le età · Tutti i sessi · Aggiornato il 10 giu 2026 · NCT05561387

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

  • M D Anderson Cancer Center, Houston
In reclutamentoFase 2
Età da 18 a 72 · Tutti i sessi · Aggiornato il 8 giu 2026 · NCT05776979

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

  • Houston Methodist Hospital, Houston
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 giu 2026 · NCT05243797

Fonte: ClinicalTrials.gov, dati recuperati il 3 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.